The Medium Chain Fatty Acid Octanoate is a Beneficial Fuel for the Failing Heart.
Why the study?
Ketone bodies reduce pathologic cardiac remodeling and dysfunction in heart failure but chronic administration is challenging, prompting investigation into whether shorter chain fatty acids like octanoate are also beneficial.
Does continuous infusion of sodium octanoate delay the progression of cardiac dysfunction in a canine model of tachypacing-induced dilated cardiomyopathy?
Comparison
Continuous infusion of sodium octanoate vs no octanoate infusion
Key result
Continuous infusion of sodium octanoate delayed the progression of systolic and diastolic cardiac dysfunction and normalized myocardial metabolism in a canine model of dilated cardiomyopathy.
Authors
Loading...
Hypothesis-generating for ketone-independent HF protection by octanoate; leaves open clinical translation pending human trials.
Does continuous infusion of sodium octanoate delay the progression of cardiac dysfunction in a canine model of tachypacing-induced dilated cardiomyopathy?
Delivery of medium-chain fatty acids like octanoate may serve as a potential actionable therapeutic for heart failure with reduced ejection fraction.
Gorgodze et al. (2026) studied Tachypacing-induced dilated cardiomyopathy (n=13). Sodium octanoate vs. No octanoate infusion was evaluated on Progression of systolic and diastolic cardiac dysfunction and myocardial metabolism. Continuous infusion of sodium octanoate delayed the progression of systolic and diastolic cardiac dysfunction and normalized myocardial metabolism in a canine model of dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: